Medicine
Emcitate 350 mcg tablet for oral suspension
Emcitate 350 mcg tablet for oral suspension is a prescription medicine containing Tiratricol for oral use, marketed by Rare Thyroid Therapeutics International, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians. It ships in a temperature-controlled cold chain.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Cold chain
Store refrigerated at 2°C to 8°C (36°F to 46°F), and keep protected from light.
Key facts
- Active ingredient (INN)
- Tiratricol
- Brand
- Emcitate
- Strength
- 350 mcg
- Dosage form
- Tablet for oral suspension
- Route
- Oral
- Packs
- 6 blister pack
- Marketing authorisation holder
- Rare Thyroid Therapeutics International
- Manufacturer
- Rare Thyroid Therapeutics International
- Origin register
- US FDA, United States
- Storage
- Store refrigerated at 2°C to 8°C (36°F to 46°F), and keep protected from light.
- Cold chain
- Yes, shipped temperature controlled
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- D11AX08 Tiratricol
- HS code (indicative)
- 3004.90Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 26 October 2026
- Identifiers
- RxCUI 2755025, 2755031DailyMed set ID 48d9faab-9c60-4abd-b4b9-97ffa778c944NDC 87216-0100Application NDA220963
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 6 blister pack in 1 carton / 10 tablet, for suspension in 1 blister pack | 87216-0100-1 | Rare Thyroid Therapeutics International | 26 October 2026 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Clinical summary
Tiratricol is a prescription medicine indicated for the treatment of peripheral thyrotoxicosis in adults and pediatric patients with monocarboxylate transporter 8 (MCT8) deficiency (Allan-Herndon-Dudley syndrome). It is available as tablet for oral suspension. MedsAcross supplies Tiratricol for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about TiratricolFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- EMCITATE prescribing information (Rare Thyroid Therapeutics International) · U.S. National Library of Medicine, DailyMed
- Emcitate: European public assessment report (EPAR) · European Medicines Agency
Need Emcitate 350 mcg tablet for oral suspension for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.